Showing 951-960 of 20877 results for "".
- Asthma in Pregnancy: ICS Continuation Not Linked to Higher Riskhttps://reachmd.com/news/asthma-in-pregnancy-ics-continuation-not-linked-to-higher-risk/2488210/Key Takeaways In women in Korea with asthma who had used ICS before pregnancy, first-trimester continuation and discontinuation were the exposure patterns compared in a nationwide live-birth cohort. First-trimester ICS discontinuation was more common than continuatio
- Early Infections Linked to Childhood Atopic Dermatitis Riskhttps://reachmd.com/news/early-infections-linked-to-childhood-atopic-dermatitis-risk/2488211/Key Takeaways Children in Danish and U.S. birth cohorts with higher early infection burden from ages 0 to 3 years had higher odds of childhood AD. AD odds increased as infection episodes and infection days accumulated, consistent with a dose-response pattern.
- Acetaminophen Tops Poison Center Liver Injury Reportshttps://reachmd.com/news/acetaminophen-tops-poison-center-liver-injury-reports/2488223/Key Takeaways Across U.S. poison-center surveillance, reported xenobiotic-associated liver injury increased over time, and most cases required inpatient care. Acetaminophen was the most frequently implicated substance in reported U.S. poison-center liver injury cases
- Injectors Report Favorable Ergonomics With HA Filler Syringe Add-onhttps://reachmd.com/news/injectors-report-favorable-ergonomics-with-ha-filler-syringe-add-on/2488229/A simulated-use study found that aesthetic healthcare professionals reported high levels of comfort, satisfaction, and perceived ergonomics when using an investigational add-on device designed for prefilled hyaluronic acid (HA) filler syringes. Study researchers evaluated a redesigned back
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://reachmd.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Skin Cancer Champions to Host Inaugural Patient Advocacy Summithttps://reachmd.com/news/skin-cancer-champions-to-host-inaugural-patient-advocacy-summit/2488209/Skin Cancer Champions will convene its inaugural Patient Advocacy Summit on October 30, 2026, in Boston, Massachusetts, bringing patients and caregivers together with clinicians and industry representatives to discuss nonmelanoma skin cancer care, emerging therapies, and patient advocacy.
- Methotrexate Timing and Influenza Vaccine Response in RAhttps://reachmd.com/news/methotrexate-timing-and-influenza-vaccine-response-in-ra/2488192/Key Takeaways In healthy-donor lymphocyte experiments paired with a post-hoc rheumatoid arthritis vaccine analysis, methotrexate suppressed activated T- and B-cell responses while largely sparing resting cells. A brief methotrexate pulse had its strongest inhibitory
- FAERS Screens 17 Drug-Associated IBD Safety Signalshttps://reachmd.com/news/faers-screens-17-drug-associated-ibd-safety-signals/2488204/Key Takeaways Across 52,395 FAERS reports representing 50,426 patients, the pharmacovigilance screen identified a defined set of suspected drug-associated inflammatory bowel disease signals. Seventeen drugs reported at least 50 times met all four prespecified signal
- IL-13 Signaling in cDC2 Links Skin Allergy to IgEhttps://reachmd.com/news/il-13-signaling-in-cdc2-links-skin-allergy-to-ige/2488206/Key Takeaways In a murine cutaneous allergen sensitization model, skin inflammation was linked to systemic anaphylaxis and positioned as a mechanistic step in the atopic march. IL-13 signaling was required in conventional dendritic cells rather than T or B cells for
- Nutrafol Introduces Updated Hair Nutraceutical for Women Aged 18–44https://reachmd.com/news/nutrafol-introduces-updated-hair-nutraceutical-for-women-aged-1844/2488189/Ten years after introducing its original Women’s Hair Growth Nutraceutical, Nutrafol has replaced the product with an updated formulation for women aged 18 to 44. The advanced formula, previously marketed as Nutrafol Women’s Vegan, builds on the company’s whole-body approach to hair health